| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6201399 | Ophthalmology | 2015 | 7 Pages |
Abstract
Once-daily oral darapladib administered for 3 months demonstrated modest improvements in vision and macular edema that warrant additional investigation of this novel lipoprotein-associated phospholipase A2 inhibitory mechanism for the treatment of DME.
Keywords
lyso-PCDMEMCP-1BCVASAEETDRSLp-PLA2Diabetic macular edemaOctbest-corrected visual acuityOptical coherence tomographySpectral domainearly treatment diabetic retinopathy studyadverse eventsevere adverse eventconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Lipoprotein-associated phospholipase A2Lysophosphatidylcholinemonocyte chemotactic protein
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Giovanni MD, Li MS, Mindy H. PhD, Ronald P. MD, John MD, MPH, Peter PhD, Megan M. MS, Darapladib DME Study Group Darapladib DME Study Group,